الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
The relation between IFNL4 (interferon lambda 4 gene) and direct acting antiviral (DAA) regimens in Egyptian hepatitis C virus (HCV) infected patients is not clear. So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration. This study aims to investigate the relation between IFNL4 polymorphisms and clearance of HCV genotype 4 for Egyptian HCV patients. Hence the appropriate drug can be chosen for each patient. SNP genotyping assay for IFNL4 which formerly known as IL28B (rs368234815) was examined for genomic DNA. The DNA was extracted from whole blood of one hundred Egyptian patients whom documented to have infection with chronic HCV genotype 4 (positive PCR) and treated with SOF and RBV. All samples were collected from Cairo University Hospitals, Egypt. Patients were diagnosed, previously, as HCV genotype 4 and classified according to drug response into two groups (responders, non-responders). All samples were compared with 50 of non-infected (negative PCR) people (control group). The TT/TT homozygous represents 48% of patients and 66% of non-infected Egyptian people while the homozygous is 21% and 12%, respectively. There is significance to IFNL4 genotypes for treatment response with probability value p < 0.001. The percentages of appearance of genotypes TT/TT, TT/ and for responders were 60%, 28% and 12%, respectively. There is no significance for gender, age, ALT, PLC, AFP, AST, TLC, Hb, TB, creatinine and RBG to treatment response to SOF and RBV, while INR has.